CTLA4 and glioblastoma: This is followed by a systematic review of the clinical trials in which immune checkpoint inhibitors (ICIs) have been evaluated in patients with a GBM that predominantly focused on cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1).